Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-18 pm EDT			5-day change	1st Jan Change
27.98 ^USD	-6.17%		-9.42%	+35.83%

May. 08	Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing	MT
May. 06	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE

Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

Published on 03/24/2026 at 06:20 pm EDT

S&P Capital IQ

NEUROGENE INC.

-6.17%

Neurogene Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported net loss was USD 90.35 million compared to USD 75.14 million a year ago. Basic loss per share from continuing operations was USD 4.24 compared to USD 4.28 a year ago.

Latest news about Neurogene Inc.

May. 08	Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing	MT
May. 06	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Apr. 28	Guggenheim Initiates Neurogene at Buy With $69 Price Target	MT
Apr. 20	Neurogene Inc. Announces Executive and Board Appointments	CI
Apr. 20	Neurogene appoints Christy Shafer as chief commercial officer and Christine Mikail, J.D., to board of directors	RE
Mar. 24	Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 03	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Feb. 26	Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome	RE
Feb. 26	Neurogene Inc. Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome	CI
Feb. 04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
Jan. 12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
Nov. 13	Gene therapy developer Neurogene's Q3 net loss widens	RE
Nov. 13	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Neurogene Inc. Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome Multidomain	CI
Nov. 12	Neurogene Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 04:40 PM

Chart Neurogene Inc.

Duration

Period

NGNE: Dynamic Chart

Company Profile

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Employees

131

Sector

Biotechnology & Medical Research

More about the company